Pharmaceutical Supply
Expanding Access to Quality Medicines in Africa Through Distribution Partnerships
Executive brief
Reliable medicine distribution depends on product quality, licensed local roles, good handling practices and a supply plan that fits the destination market.
Decision focus
Assess whether a distribution arrangement can protect product quality, lawful supply and traceability through to the intended customer.
Process and deliverables
Define product and destination
The procurement and regulatory teams specify the exact product, intended use and destination. Output: a product-country requirements list confirmed by competent authorities or qualified advisers.
Qualify the supply chain
Verify manufacturers, suppliers, distributors and their relevant authorisations. Output: a controlled quality dossier and a map of who owns each storage, transport and reporting duty.
Validate handling and continuity
Quality and logistics teams confirm product-specific conditions, monitoring, inventory, replenishment and exception arrangements. Output: a documented operating route and escalation procedure.
Release, monitor and review
Authorised quality personnel review evidence before release and record batch movement, complaints and recall readiness. Output: a shipment record and periodic supplier-performance review.
No commercial introduction substitutes for product registration, quality assurance or the responsibilities of licensed supply-chain participants.
A practical planning framework, not legal, regulatory, technical or investment advice. Confirm requirements for the specific product, country and mandate.
In-depth analysis
A distribution partnership can help a quality-assured medicine reach the organisations and patients who need it, but the relationship is only one part of a regulated supply chain. Product authorisation, quality systems, import permissions, storage, transport, forecasting and local responsibility all have to fit the destination market.
Define product and pathway
The first step is to define the product and intended pathway. A manufacturer should identify the exact product, presentation, packaging, shelf life, manufacturing and quality documentation, and markets it is prepared to serve. A potential distributor should clarify the countries it covers, its licences and the customers or procurement channels it can support. A hospital, government buyer or institutional customer should state its need, procurement route, expected timing and relevant product requirements.
The next step is to confirm the regulatory route for each country. Requirements can differ by product, intended use and destination. A product may need registration or other authorisation before it can be imported or marketed. The parties should identify the national medicines regulator and qualified regulatory advisers who can confirm the correct process. International prequalification or quality references can be useful evidence, but they do not automatically replace national registration or local import permissions.
Check distribution capability
Distribution capability should be assessed in practical terms. Ask how the distributor receives, stores and dispatches products, how it monitors environmental conditions when required, how it manages stock rotation and expiry, and what records are kept. For products with special handling requirements, confirm that facilities, transport and staff procedures can maintain the specified conditions throughout the journey. The manufacturer and local distributor should agree who monitors deviations and how affected products are handled.
Forecasting and procurement planning are also important. Buyers and distributors should communicate expected demand, order lead times, minimum order quantities, supply continuity, payment terms and the process for changes in forecast. Planning should account for approvals and shipping time rather than assuming that a product can be delivered immediately after a commercial agreement. Clear records reduce the chance that parties make incompatible assumptions about availability.
The documentation should make responsibilities visible. This may include product and quality documents, manufacturing and batch information, registration status, import licences, storage and handling procedures, transport records, purchase orders and delivery records. The exact documents depend on the product and country. Parties should use current requirements from the competent authority and retain records in a way that supports traceability and recall procedures.
Verification needs to cover both sides. A manufacturer should check the distributor’s legal identity, authorisations, operating capacity and intended channels. A buyer should confirm that the proposed supplier and product fit its purchasing and regulatory requirements. The distributor should confirm that the manufacturer can support the market, provide the required documents and meet the agreed supply conditions. Each party should know who is legally responsible for importation, promotion, storage, sale and pharmacovigilance where applicable.
Clarify responsibilities
Commercial agreements should not blur these obligations. They should specify territory, product scope, forecast assumptions, order and payment terms, delivery responsibilities, handling requirements, quality complaints, recall cooperation and termination conditions. Exclusivity, if proposed, should be tied to clear expectations and reviewed by legal advisers. A facilitator can coordinate discussion, but licensed parties and qualified professionals remain responsible for regulatory and clinical decisions.
Transparency is particularly important when a supply arrangement involves several intermediaries. The parties should be able to identify the manufacturer, authorised distributor, importer and buyer, and understand what each is expected to do. Before sharing sensitive commercial information, confirm the authority behind the approach and agree suitable confidentiality terms.
Afrivaar Global Solutions facilitates pharmaceutical and medical-supply distribution discussions into African markets. We help organise the commercial pathway, request relevant documentation and connect verified counterparties. We do not register products, replace national regulators, provide medical advice or guarantee supply. Country-specific regulatory, quality and professional advice should be obtained before a product is imported or distributed.
Quality assurance also depends on traceability after a shipment arrives. The parties should agree how batches are recorded, how complaints are escalated, who can quarantine affected stock and how a recall would be coordinated if a quality concern appears. A documented process needs named responsibilities and workable contact routes, not only a clause in a contract. Buyers should check that the proposed distributor can maintain the records and handling procedures required for the product.
The World Health Organization's prequalification program publishes assessments and information on medical products that meet its applicable evaluation processes. That information can support procurement review, but buyers still need to establish whether the product and supplier meet the destination country's requirements and the tender's conditions. Product status, formulation, manufacturer, packaging and intended market all matter. Confirm the current position with the relevant regulator and qualified specialists rather than relying on an old catalogue or a general claim of approval.
Access depends on practical fit as well as regulatory permission. A supply plan should reflect how healthcare providers order, store and use the product, whether delivery sizes suit their capacity and how stock availability will be communicated. Forecasts should be treated as planning inputs, not guaranteed demand. Clear communication between manufacturer, importer, distributor and buyer can reduce avoidable mismatches while preserving each party's responsibility for quality and patient safety.